Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction : Eligibility Based on Randomized Trials Supporting European and American Guidelines
Copyright © 2023. Published by Elsevier Inc..
OBJECTIVE: We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction from the EPICOR registries.
METHODS: Recommendations provided by American and European guidelines for acute myocardial infarction were classified into general (applying to all patients) and specific (applying to patients with left ventricular dysfunction or heart failure). Randomized controlled trials cited in these recommendations were selected, and their entry criteria were applied to our international cohort of 18,117 patients.
RESULTS: There were 91.5% patients eligible for beta blockers (84.6% for general, and 5.9% for specific recommendations), 97.7% eligible for renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [ACEI/ARB]) recommendations (69.9% for general, 27.9% for specific) and 4.1% eligible for mineralocorticoid receptor antagonists (only specific recommendations). The percentages of patients with eligibility criteria who were discharged with a prescription of the recommended therapies were 80%-85% for beta blockers, 70%-75% for ACEI/ARB, and 29% for mineralocorticoid receptor antagonists. There were large regional variations in the percentage of eligible patients and in those receiving the medications (eg, 95% in Northern Europe and 57% in Southeast Asia for beta blockers).
CONCLUSION: Most real-world acute myocardial infarction patients are eligible for secondary prevention therapy in both general and specific guideline recommendations, and the percentage of those on beta blockers and ACEI/ARB at hospital discharge is high. There are large regional variations in the proportion of patients receiving recommended therapies. Local targeted interventions are needed for quality improvement.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
|---|---|
| Enthalten in: |
The American journal of medicine - 137(2024), 2 vom: 25. Feb., Seite 137-146.e10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mas-Llado, Caterina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.02.2024 Date Revised 02.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjmed.2023.09.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363311939 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363311939 | ||
| 003 | DE-627 | ||
| 005 | 20240202232025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjmed.2023.09.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM363311939 | ||
| 035 | |a (NLM)37838236 | ||
| 035 | |a (PII)S0002-9343(23)00613-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mas-Llado, Caterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction |b Eligibility Based on Randomized Trials Supporting European and American Guidelines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVE: We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction from the EPICOR registries | ||
| 520 | |a METHODS: Recommendations provided by American and European guidelines for acute myocardial infarction were classified into general (applying to all patients) and specific (applying to patients with left ventricular dysfunction or heart failure). Randomized controlled trials cited in these recommendations were selected, and their entry criteria were applied to our international cohort of 18,117 patients | ||
| 520 | |a RESULTS: There were 91.5% patients eligible for beta blockers (84.6% for general, and 5.9% for specific recommendations), 97.7% eligible for renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [ACEI/ARB]) recommendations (69.9% for general, 27.9% for specific) and 4.1% eligible for mineralocorticoid receptor antagonists (only specific recommendations). The percentages of patients with eligibility criteria who were discharged with a prescription of the recommended therapies were 80%-85% for beta blockers, 70%-75% for ACEI/ARB, and 29% for mineralocorticoid receptor antagonists. There were large regional variations in the percentage of eligible patients and in those receiving the medications (eg, 95% in Northern Europe and 57% in Southeast Asia for beta blockers) | ||
| 520 | |a CONCLUSION: Most real-world acute myocardial infarction patients are eligible for secondary prevention therapy in both general and specific guideline recommendations, and the percentage of those on beta blockers and ACEI/ARB at hospital discharge is high. There are large regional variations in the proportion of patients receiving recommended therapies. Local targeted interventions are needed for quality improvement | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myocardial infarction | |
| 650 | 4 | |a Clinical practice guidelines | |
| 650 | 4 | |a Randomized controlled trials | |
| 650 | 4 | |a Real-world registry | |
| 650 | 7 | |a Mineralocorticoid Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 700 | 1 | |a Rossello, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a González-Del-Hoyo, Maribel |e verfasserin |4 aut | |
| 700 | 1 | |a Pocock, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a de Werf, Frans Van |e verfasserin |4 aut | |
| 700 | 1 | |a Chin, Chee Tang |e verfasserin |4 aut | |
| 700 | 1 | |a Danchin, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Stephen W-L |e verfasserin |4 aut | |
| 700 | 1 | |a Medina, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno, Héctor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of medicine |d 1946 |g 137(2024), 2 vom: 25. Feb., Seite 137-146.e10 |w (DE-627)NLM000114472 |x 1555-7162 |7 nnns |
| 773 | 1 | 8 | |g volume:137 |g year:2024 |g number:2 |g day:25 |g month:02 |g pages:137-146.e10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjmed.2023.09.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 137 |j 2024 |e 2 |b 25 |c 02 |h 137-146.e10 | ||